| Lan, Qing |
| Recruiting | 1 | 50 | RoW | Tumor Infiltrating Lymphocytes (TIL) | Shanghai Juncell Therapeutics, Second Affiliated Hospital of Soochow University | Glioma | 12/24 | 05/25 | | |
| Jiang, Guoqin |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Xu, Li |
NCT04454905: Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study |
|
|
| Recruiting | 2 | 50 | RoW | Camrelizumab, Camrelizumab for Injection, Apatinib, Rivoceranib | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Intrahepatic Cholangiocarcinoma | 07/24 | 07/25 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
| Zhang, Xia |
NCT06711991: A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease |
|
|
| Not yet recruiting | 1 | 48 | RoW | TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 12/25 | 01/26 | | |
| Tang, Wen |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
NCT05387031: Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease |
|
|
| Recruiting | N/A | 239 | RoW | Ustekinumab, Stelara | Second Affiliated Hospital, School of Medicine, Zhejiang University, Sixth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Soochow University, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Seventh Medical Center of PLA Army General Hospital, First People's Hospital of Hangzhou, Yangzhou University, Xian-Janssen Pharmaceutical Ltd. | Crohn Disease, Stricture; Bowel, Intestinal Stricture | 08/26 | 08/27 | | |
| Li, Hui |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT06753890: Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) |
|
|
| Not yet recruiting | 3 | 520 | RoW | Changkang granules, Changkang Granules placebo | Tasly Pharmaceutical Group Co., Ltd | Diarrhea-predominant Irritable Boewl Syndrome | 11/26 | 12/26 | | |
NCT05555706: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2/3 | 450 | RoW | B013+Nab-Paclitaxel | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Triple Negative Breast Cancer (TNBC) | 06/25 | 12/26 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT05987371: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. |
|
|
| Recruiting | 2 | 72 | RoW | TQC3721 suspension for inhalation, TQC3721 matching placebo for inhalation, Salbutamol sulfate inhalation aerosol | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 01/24 | 03/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
| Recruiting | N/A | 4500 | RoW | | Harbin Medical University, Abbott | Acute Myocardial Infarction | 07/21 | 12/22 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04953117: A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel Disease |
|
|
| Recruiting | N/A | 286 | RoW | DCB of Lepu Medical(dimeter≥2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary small vessels, Restore DEB, RESTORE Paclitaxel releasing coronary balloon catheter, DCB of Lepu Medical(dimeter<2.00 mm), Coronary Drug Coated Balloon Catheter of Lepu Medical for coronary very small vessels | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease | 06/22 | 04/23 | | |
REAL, NCT05970159: Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery |
|
|
| Recruiting | N/A | 480 | RoW | | Shanghai Zhongshan Hospital, Takeda | Hepatocellular Carcinoma | 06/24 | 03/25 | | |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
| Wang, Hui |
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. |
|
|
| Recruiting | 3 | 192 | RoW | Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment | Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 12/24 | 12/26 | | |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
| Not yet recruiting | 3 | 358 | RoW | TQB2450+Anlotinib, TQB2450 placebo + Anlotinib placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer Limited Stage | 09/26 | 09/26 | | |
NCT06000956: A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo |
|
|
| Recruiting | 3 | 408 | RoW | Jitongning tablets, a simulated agent of Jitongning tablets | Tasly Pharmaceutical Group Co., Ltd | Ankylosing Spondylitis | 12/26 | 12/26 | | |
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 190 | RoW | HX008, Investigator's Choice Chemotherapy | Taizhou Hanzhong biomedical co. LTD | Metastatic Colorectal Cancer | 01/26 | 10/28 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT04922450: Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | PD-1 inhibitor, Albumin Paclitaxel, Cisplatin | Hunan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd. | Head and Neck Cancer, Squamous Cell Carcinoma | 01/23 | 01/23 | | |
NCT05815862: Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer |
|
|
| Recruiting | 2 | 40 | RoW | AL2846 capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Lung Cancer, Ovarian Cancer | 06/24 | 12/24 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
AK104-IIT-024, NCT05824494: Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | 2 | 58 | NA | Cadonilimab, Nab paclitaxel | Women's Hospital School Of Medicine Zhejiang University, Akeso | Uterine Cervical Neoplasms, Cancer of Cervix, Cervical Cancer, Cervical Neoplasms, Uterine Cervical Cancer, Cancer of the Uterine Cervix | 06/26 | 06/26 | | |
NCT05794477: A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 132 | RoW | Adebrelimab, SHR-1802, Carboplatin/Cisplatin, Paclitaxel/Nab-Paclitaxel/Pemetrexed | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Active, not recruiting | 1 | 45 | RoW | ICVAX, Placebo | Immuno Cure Holding (HK) Limited, Shenzhen Third People's Hospital, Shenzhen Immuno Cure Biomedical Company Limited | Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection | 09/24 | 01/25 | | |
| Recruiting | 1 | 15 | RoW | Autologous tumor-infiltrating lymphocyte cells | Hervor Therapeutics, Jinling Hospital, China, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Women's Hospital School Of Medicine Zhejiang University | Advanced Solid Tumor | 12/25 | 12/26 | | |
NCT05606848: To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer |
|
|
| Recruiting | N/A | 350 | RoW | Nutrition Emulsion (TPF-T), Foods for special medical purposes [FSMP] for patients with tumors | Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd | Gastrointestinal Cancer | 03/25 | 03/25 | | |
| Li, Feng |
| Recruiting | 2 | 60 | RoW | adjuvant tislelizumab and chemotherapy for MRD+ patients, adjuvant chemotherapy for MRD- patients | The First Affiliated Hospital of Zhengzhou University, BeiGene | NSCLC | 06/26 | 06/27 | | |
NCT06697665: An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 10 | RoW | LM103 | Suzhou BlueHorse Therapeutics Co., Ltd. | Solid Cancer | 01/26 | 06/27 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
| Liu, Chun-Feng |
NCT06195124: A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease |
|
|
| Recruiting | 1 | 8 | RoW | RGL-193（low-dose）, RGL-193（high-dose） | Second Affiliated Hospital of Soochow University, Shanghai Regenelead Therapies Co., Ltd. | Advanced Parkinson's Disease | 12/24 | 12/24 | | |
| Zhang, Jian |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 12/25 | 12/25 | | |
NCT05949801: Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 202 | RoW | Neucardin, Recombinant human Neuregulin-1 for Injection, Placebo, Excipients of recombinant human neuregulin-1 freeze dried for injection | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 08/24 | 10/24 | | |
| Recruiting | 3 | 224 | RoW | DB-1303/BNT323, T-DM1 | DualityBio Inc., BioNTech SE | HER2-positive Breast Cancer | 02/26 | 02/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. |
|
|
| Not yet recruiting | 3 | 200 | RoW | T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection | Changchun GeneScience Pharmaceutical Co., Ltd. | Breast Cancer Subjects | 11/25 | 03/26 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 406 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-Negative Breast Cancer | 06/26 | 06/26 | | |
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Triple Negative Breast Cancer | 08/26 | 06/27 | | |
NCT06680921: A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE) |
|
|
| Recruiting | 3 | 460 | RoW | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 08/28 | 08/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT04778982: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer |
|
|
| Terminated | 2 | 4 | RoW | KN026 combined with Palbociclib and Fulvestrant, combination | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | HER2-positive Metastatic Breast Cancer | 03/23 | 03/23 | | |
NCT06413615: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 150 | RoW | FDA022-BB05 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/25 | 06/26 | | |
NCT06492005: A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 160 | RoW | 9MW2821, PD-1 inhibitior | Mabwell (Shanghai) Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 07/26 | 07/27 | | |
NCT06471205: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-negative Breast Cancer | 07/26 | 07/26 | | |
NCT06042894: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 58 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT05785728: A Study of DB-1202 Monotherapy in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 150 | RoW | DB-1202 | DualityBio Inc. | Advanced Solid Tumor | 02/24 | 02/24 | | |
NCT04282031: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer |
|
|
| Recruiting | 1/2 | 224 | RoW | BPI-1178, Fulvestrant, Letrozole | Beta Pharma (Suzhou) Co., Ltd. | Advanced Solid Tumor, HR+/HER2- Breast Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 181 | US, RoW | MRG004A | Shanghai Miracogen Inc. | Advanced or Metastatic Solid Tumors | 04/24 | 06/25 | | |
NCT05048160: A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm |
|
|
| Recruiting | 1/2 | 272 | RoW | Intravenous Infusion | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Neoplasm | 06/24 | 12/24 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
NCT05301764: A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 65 | RoW | LVGN6051 and Anlotinib | Lyvgen Biopharma Holdings Limited | Soft Tissue Sarcoma | 03/25 | 10/25 | | |
NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies |
|
|
| Recruiting | 1/2 | 32 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gynecological Malignant Tumor, Solid Tumor | 06/25 | 06/25 | | |
NCT05842785: TSN222 in Subjects With Advanced Solid Tumors or Lymphomas |
|
|
| Recruiting | 1/2 | 162 | RoW | Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma, Phase II-solid tumors or lymphomas | Tyligand Bioscience (Shanghai) Limited | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | 06/25 | 06/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 208 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 12/25 | 12/25 | | |
NCT05416749: A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 216 | RoW | 8MW2311 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 03/26 | 03/26 | | |
NCT05463432: A Study of HR19024 in Subjects With Advanced Solid Tumor |
|
|
| Recruiting | 1a | 180 | RoW | HR19024 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
| Completed | 1 | 23 | RoW | Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002., Biological Products, Humanized Anti-HER2 Monoclonal Antibody Compound for Injection | Shanghai Pharmaceuticals Holding Co., Ltd | Recurrent Breast Cancer, Metastatic Breast Cancer | 04/22 | 04/22 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06299124: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | RGT-419B, Active drug | Regor Pharmaceuticals Inc. | Breast Cancer, Advanced Solid Tumor | 12/24 | 06/25 | | |
NCT04631835: Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 54 | RoW | HS-10352 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Breast Cancer | 04/23 | 08/23 | | |
NCT05221385: Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma |
|
|
| Terminated | 1 | 58 | RoW | Gentulizumab | Changchun GeneScience Pharmaceutical Co., Ltd. | Solid Tumor, Non-Hodgkin Lymphoma | 05/23 | 10/23 | | |
NCT05078593: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma |
|
|
| Completed | 1 | 18 | RoW | HLX26, Anti-LAG-3 Monoclonal Antibody | Shanghai Henlius Biotech | Solid Tumor, Adult, Lymphoma | 08/23 | 08/23 | | |
| Completed | 1 | 28 | RoW | AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus | AstraZeneca | ER+, HER2-, Metastatic Breast Cancer | 09/23 | 09/23 | | |
NCT05337657: A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 10 | RoW | GB491+Letrozole | Genor Biopharma Co., Ltd. | Advanced Breast Cancer | 12/23 | 02/24 | | |
NCT06761651: A Study of TAVO412 in Patients with Cancer (TAVO412) |
|
|
| Recruiting | 1 | 50 | RoW | TAVO412 | Tavotek Biotherapeutics | Cancer | 01/26 | 10/26 | | |
NCT06172322: A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer |
|
|
| Recruiting | 1 | 42 | RoW | NTQ1062 with Fulvestrant | Nanjing Chia-tai Tianqing Pharmaceutical | HR Positive/HER-2 Negative Breast Cancer | 04/25 | 07/25 | | |
NCT05360368: HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 24 | RoW | HLX07, Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection | Shanghai Henlius Biotech | Solid Tumor | 12/23 | 02/24 | | |
| Recruiting | 1 | 177 | RoW | HS-20089 (Phase Ia：Dose escalation ), HS-20089 (Phase Ib: Dose expansion) | Shanghai Hansoh Biomedical Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT05263180: A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. |
|
|
| Recruiting | 1 | 30 | RoW | EMB-09 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05498597: AMT-151 in Patients With Selected Advanced Solid Tumours |
|
|
| Recruiting | 1 | 30 | RoW | AMT-151 | Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd | Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer, Ovarian Carcinoma, Ovarian Epithelial Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Lung Adenocarcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Pleural Mesothelioma, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma | 01/24 | 10/24 | | |
NCT06219356: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas |
|
|
| Recruiting | 1 | 110 | RoW | GLB-002, GLB-A062-B | Hangzhou GluBio Pharmaceutical Co., Ltd. | Non-Hodgkin Lymphoma | 01/26 | 02/27 | | |
NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. |
|
|
| Terminated | 1 | 24 | US, RoW | CYH33, Olaparib | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer | 02/23 | 02/23 | | |
NCT05509790: A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer |
|
|
| Active, not recruiting | 1 | 17 | RoW | LY3484356 | Eli Lilly and Company | Breast Neoplasms | 02/24 | 12/25 | | |
| Recruiting | 1 | 66 | RoW | Q-1802 | QureBio Ltd. | Advanced Solid Tumors | 04/24 | 07/24 | | |
NCT04893759: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 60 | RoW | Pelcitoclax, APG-1252 | Ascentage Pharma Group Inc. | Neuroendocrine Tumors | 06/24 | 06/25 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
BL-B01D1-104, NCT05470348: A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 06/25 | 12/25 | | |
NCT05394168: A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | HLX53 | Shanghai Henlius Biotech | Advanced/Metastatic Solid Tumors | 12/24 | 03/25 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
BL-M17D1-101, NCT06503783: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 08/26 | 08/26 | | |
BL-B16D1-103, NCT06493864: A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 21 | RoW | BL-B16D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 07/26 | 07/26 | | |
